Bleomycin Electrosclerotherapy (BEST) for treatment of slow-flow vascular malformations in children
Bleomycin Electrosclerotherapy (BEST) is a safe and effective treatment for slow-flow vascular malformations in pediatric patients, achieving lesion volume reduction and symptom improvement. The study assesses BEST exclusively in a pediatric cohort using standardized MRI-based volumetry alongside clinical outcomes. BEST can be effective not only in refractory cases but also as a first-line or early-line treatment option, broadening its potential indications. By indicating a cumulative therapeutic benefit of repeated BEST sessions, the study encourages further investigations into tailored, session-based treatment strategies for large or progressive malformations.
Authors
- Marie-Sophie Schüngel
- Vanessa F. Schmidt (ORCID: https://orcid.org/0000-0002-7067-2203)
- Moritz Wildgruber (ORCID: https://orcid.org/0000-0002-7228-6963)
- Richard Brill (ORCID: https://orcid.org/0000-0002-1875-4463)
- Moritz Guntau
- Alena Akinina
- Constantin Goldann (ORCID: https://orcid.org/0000-0002-2133-7935)
- Julius Henry Loeser (ORCID: https://orcid.org/0009-0003-8644-690X)
- Walter Alexander Wohlgemuth (ORCID: https://orcid.org/0000-0002-8076-6000)
- Anna Deleu
Institutions
- Universitätsklinikum Würzburg (DE)
- München Klinik Harlaching (DE)
- University Hospital in Halle (DE)
- Technical University of Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Pediatric Research
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1038/s41390-025-04455-6
- Citations
- 1
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 2.01